Compare HRMY & RUN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | RUN |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2020 | 2015 |
| Metric | HRMY | RUN |
|---|---|---|
| Price | $36.75 | $8.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 19 |
| Target Price | ★ $48.08 | $14.21 |
| AVG Volume (30 Days) | 993.4K | ★ 8.5M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.97 | ★ 113.35 |
| EPS | ★ 1.84 | 1.04 |
| Revenue | ★ $868,453,000.00 | $858,578,000.00 |
| Revenue This Year | $18.17 | $4.94 |
| Revenue Next Year | $13.71 | $3.38 |
| P/E Ratio | $20.01 | ★ $8.37 |
| Revenue Growth | ★ 21.51 | 12.97 |
| 52 Week Low | $25.90 | $6.78 |
| 52 Week High | $43.49 | $21.95 |
| Indicator | HRMY | RUN |
|---|---|---|
| Relative Strength Index (RSI) | 50.13 | 62.12 |
| Support Level | $36.74 | $8.34 |
| Resistance Level | $39.40 | $9.17 |
| Average True Range (ATR) | 1.50 | 0.46 |
| MACD | 0.17 | 0.16 |
| Stochastic Oscillator | 80.36 | 99.62 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.